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Abstract
Aims/hypothesis Human embryonic stem cells (hESCs) and
human induced pluripotent stem cells (hIPSCs) offer unique
opportunities for regenerative medicine and for the study of
mammalian development. However, developing methods to
differentiate hESCs/hIPSCs into specific cell types following
a natural pathway of development remains a major challenge.
Methods We used defined culture media to identify signal-
ling pathways controlling the differentiation of hESCs/
hIPSCs into pancreatic or hepatic progenitors. This ap-
proach avoids the use of feeders, stroma cells or serum, all
of which can interfere with experimental outcomes and
could preclude future clinical applications.
Results This study reveals, for the first time, that activin/
TGF-β signalling blocks pancreatic specification induced
by retinoic acid while promoting hepatic specification in
combination with bone morphogenetic protein and fibro-
blast growth factor. Using this knowledge, we developed
culture systems to differentiate human pluripotent stem cells
into near homogenous population of pancreatic and hepatic
progenitors displaying functional characteristics specific to
their natural counterparts. Finally, functional experiments
showed that activin/TGF-β signalling achieves this essential
function by controlling the levels of transcription factors
necessary for liver and pancreatic development, such as
HEX and HLXB9.
Conclusion/interpretation Our methods of differentiation
provide an advantageous system to model early human
endoderm development in vitro, and also represent an im-
portant step towards the generation of pancreatic and hepatic
cells for clinical applications.
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Introduction
Production of pancreatic beta cells is a major objective of
regenerative medicine. An increased supply of these cells
will enable the development of cell-based therapy against
diabetes, which is currently limited by the lack of donated
organs and difficulties with increasing insulin-secreting cells
in vitro. Human pluripotent stem cells (hPSCs) of embry-
onic origin (human embryonic stem cells [hESCs]) [1] or
generated from reprogrammed somatic cells (human in-
duced pluripotent stem cells [hIPSCs]) [2] offer the prospect
of bypassing these restrictions. These cells are capable of
proliferating indefinitely in vitro while maintaining the ca-
pacity to differentiate into a broad number of cell types,
including pancreatic progenitors [3–6]; however, robust pro-
tocols allowing for the production of homogenous popula-
tions of these cells in defined culture conditions have not yet
been established. Current methods involve undefined ani-
mal products such as feeders, FBS and Matrigel and only
allow for the generation of heterogeneous populations of
cells, thus increasing the risk of teratoma formation after
transplantation [7, 8]. They also appear to work efficiently
on a limited number of hPSC lines [3], which hinders their
use in a large number of laboratories.
Most of the culture systems currently used to direct the
differentiation of hPSCs mimic normal development, since
this approach could facilitate the generation of fully func-
tional cell types. Consequently, the knowledge coming from
studies on mice or other vertebrate animal models has been
used to inform strategies driving hPSCs towards specific
lineages. The pancreas and liver arise at approximately
embryonic day 8.5–9.5 from adjacent regions of the devel-
oping primitive foregut under the influence of inductive
signals secreted by the nearby mesoderm [9]. These signals
probably command the production of transcription factors
necessary for pancreatic specification, such as HLXB9,
which marks the dorsal foregut (DF) prior to the formation
of the pancreatic bud [10, 11], and PDX1, which marks
regions of the foregut from which the ventral and dorsal
pancreatic buds arise [12, 13]. The newly specified pancre-
atic endoderm quickly produces additional markers, includ-
ing PTF1A, NKX6.1 and SOX9, and these progenitors give
rise to both endocrine (islets of Langerhans) and exocrine
(acinar and ductal cells) cells of the pancreas. Similar mech-
anisms control hepatic specification, although they involve a
different set of transcription factors, such as homeobox
protein (HEX), GATA-binding factor 6 (GATA6), Prospero
homeobox protein 1 (PROX1) and hepatic nuclear factor 4α
(HNF4A) [14], and signalling pathways, such as bone
morphogenetic protein (BMP) and fibroblast growth
factors (FGFs) [15]. Despite this broad knowledge, the
molecular mechanisms enabling extracellular signalling
pathways to orchestrate the transcriptional networks
characterising pancreatic or hepatic progenitors remain
to be elucidated. Especially in humans, hPSCs could
present a unique advantage in completing this major
task.
In the current study, we screened defined culture condi-
tions to differentiate human definitive endoderm (DE) from
multiple hPSC lines into a near homogenous population of
pancreatic endoderm cells. Our analyses revealed that
activin/TGF-β controls DE cell fate choice between the
pancreatic and hepatic lineages by controlling the levels of
key transcription factors. These observations facilitated the
development of defined culture systems to differentiate
DE cells into near homogenous populations of pancre-
atic and hepatic endoderm following a natural path of
development. Therefore, the method described here not
only provides a unique in vitro model of development
for basic studies, but also represents a first step towards
the production of pancreatic and hepatic cell types for
therapeutic use.
Methods
hESC and hIPSC culture conditions hESCs (H9 from
WiCell, Maddison, WI, USA) and hIPSCs (BBHX8,
A1ATD-1, JRO1D; University of Cambridge, Cambridge,
UK) [16] were passaged weekly using collagenase IV and
maintained in chemically defined medium (CDM) supple-
mented with activin A (10 ng/ml) and FGF2 (12 ng/ml), as
described previously [17]. Differentiation was carried out as
described in Fig. 1 and is explained in detail in the electronic
supplementary material (ESM) Methods.
RT-qPCR, immunostaining, FACS analyses and HEX/
HLXB9 knockdown The methods used for RT-quantitative
(q)PCR, immunostaining and FACS analyses have been
described elsewhere [18, 19] and are outlined in the ESM
Methods and ESM Table 1. All data are presented as aver-
age of three independent biological triplicates and error bars
indicate SDs.
C-peptide release, cytochrome P450 activity, periodic acid
Schiff and LDL-cholesterol uptake assays C-peptide ELISA
(Mercodia, Uppsala, Sweden), Cyp3A4 P450-Glo assays
(Promega, Maddison, WI, USA), periodic acid Schiff
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staining (Sigma, St Louis, MO, USA) and 1,1′-dioctadecyl-
3,3,3′,3′-tetramethylindocarbocyanine-labelled acetylated
LDL (Dil-LDL) uptake (Cayman Chemicals, MA, USA)
were measured in triplicate according to the manufacturers’
instructions.
Microarray profiling RNA was hybridised to Illumina (San
Diego, CA, USA) HumanHT-12 v4.0R1 Expression Bead-
Chips using the manufacturer’s standard protocols. BeadChip
probe sets that did not pass the Illumina signal detection
statistic at a threshold of p<0.01 in all sample replicates of at
least one sample group were removed from further analysis.
Array processing was performed using the BeadArray package
of the Bioconductor suite of software (www.bioconductor.org)
for the R statistical programming language (www.r-project.
org). See ESM for more detailed methods.
Animal studies Differentiated cells (5×106) were grafted
under the kidney capsule of NOD/severe combined immu-
nodeficiency (SCID) mice using a 24G catheter attached to a
positive displacement pipette. Blood samples were removed
from the tail at various time intervals for C-peptide analysis.
Kidneys were harvested at the indicated time points, and a
section containing the grafted cells was fixed in 4%
paraformaldehyde, wax embedded and processed for immu-
nohistochemistry. Antibody binding was visualised using
3,3′-diaminobenzidine.
Ethics approvals Ethics approval was obtained for hPSCs
(authorisation 09/H0306/73 and 08/H0311/201) and hESCs
were imported under the guidelines of the UK Stem Cell
Bank Steering Committee (authorisation SCSC10-44).
All animal experiments were conducted following UK
regulations under the project licence PPL60/4242. Animals
were sourced from Harlan laboratories (Indianapolis, IN,
USA).
Results
Inhibition of activin and BMP signalling in the presence
of retinoic acid induces PDX1 expression in hESC-
derived endoderm cells grown in fully defined culture
conditions We recently established a defined culture system
to differentiate hESCs and hIPSCs into near homogenous
populations of DE cells [20]. This culture system relies on a
CDM devoid of animal product including BSA, serum,
complex extracellular matrix such as Matrigel (BD Bio-
sciences, NJ, USA) or feeder cells, thereby avoiding the
presence of unknown factors that might interfere with ex-
perimental outcomes. To further extend this protocol, we
screened a broad number of combinations of growth factors
and inhibitors of signalling pathways to identify defined
culture conditions driving the differentiation of DE cells
into pancreatic progenitors. These analyses revealed that a
combination of retinoic acid (RA), FGF10, noggin (a BMP
inhibitor) and SB431542 (SB; an activin/TGF-β receptor
antagonist) was able to induce expression of the pancreatic
markers PDX1, HNF6, PTF1A, SOX9 and HLXB9 (also
known as MNX1), while inhibiting the expression of gut
(CDX2) and liver (AFP) markers in hESC-derived DE cells
(Fig. 2a–g). Importantly, this cocktail of factors only in-
duced PDX1 in specific basal medium (advanced DMEM)
while the presence of serum, Matrigel or feeders (ESM
Fig. 1 Protocols to generate
hepatic and pancreatic endoderm
from hESCs and hIPSCs.
Successive culture conditions
driving differentiation of
pluripotent stem cells towards
pancreatic endoderm and hepatic
endoderm. A, activin; ADV,
advanced DMEM; B, BMP;
CMRL, Connaught Medical
Research Laboratories medium;
CYCP, cytochrome P450; DAPT,
N-(N-[3,5-diflurophenylacetyl]-
L-alanyl)-S-phenylglycine t-butyl
ester; F, FGF; HGF, hepatocyte
growth factor; Ly, LY294002;
Nog, noggin; OSM, oncostatinM
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Fig. 1a–c and data not shown) inhibited pancreatic endo-
derm differentiation, confirming that DE differentiation can
be influenced by a diversity of factors.
We then sought to validate and optimise the role of each
of these additives. Absence of RA in the presence of noggin,
FGF10 and SB inhibited the expression of pancreatic
markers (Fig. 2a–c and ESM Fig. 1d–f), confirming that
RA is necessary for the induction of pancreatic specification
[21]. Absence of noggin or addition of BMP4 at any time
during the differentiation process (Fig. 2a–g and ESM
Fig. 1g–i) resulted in a significant decrease in the expression
of pancreatic endoderm markers while inducing gut (CDX2)
Fig. 2 Differentiation of hESC-
derived DE into pancreatic
endoderm in defined culture
conditions. (a–g) Function of RA,
BMP, FGF10 and activin/TGF-β
on pancreatic differentiation of
DE cells generated from hESCs.
qPCR analyses showing the
expression of PDX1, HLXB9,
HNF6, CDX2, AFP, SOX9 and
PTF1A genes in DE cells grown
for 6 days in the presence of
diverse combinations of RA (R),
SB (S), activin 50 ng/ml (A),
FGF10 50 ng/ml (F) or SU5402
10 μmol/l (Su), and noggin
150 ng/ml (N) or BMP4 10 ng/
ml (B). Gene expression was
normalised to DE cells differen-
tiated for 6 days in the presence
of RA, FGF10, noggin and SB.
(h–m) Successive expression of
markers showing patterning
from pluripotency (h) to DE (i),
into the foregut (j) and then
successive differentiation
towards pancreatic endoderm
(k, l) and hormone-expressing
cells (m). All time points were
normalised to undifferentiated
hESC (time day 0). (n, o) FACS
analyses showing expression of
CXCR4 (n) in DE cells (day 3)
and PDX1 (o) in pancreatic
endoderm (day 12).
Insert shows isotype control.
Conjugated isotype control were
used as negative controls to gate
the positive population. (p–t)
Coexpression of PDX1 and
diverse pancreatic endoderm
markers in DE cells grown for
12 days in culture conditions
inductive for pancreatic
specification. Scale bar 50 μm
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and liver (AFP) markers, thereby reinforcing previous
studies showing that BMP signalling inhibits pancreatic
specification to promote alternative cell fate [22]. Inhibition
of FGF signalling using SU5402 (an FGF receptor antago-
nist) or increasing the dose of FGF10 did not affect the
expression of pancreatic endoderm markers such as PDX1,
SOX9 and HLXB9 (Fig. 2a–g, ESM Fig. 1j–o). However, the
expression of the gut marker CDX2 [23] was augmented and
the expression of PTF1A was strongly reduced in the
absence of FGF signalling, suggesting that FGF10 might
block the specification of PDX1-expressing cells towards
duodenum [23, 24] during pancreatic bud specification.
Furthermore, FGF inhibition caused significant cell death,
implying that FGFs are also necessary for the proliferation
and survival of pancreatic endoderm in vitro. More impor-
tantly, we observed that the addition of activin abolished the
expression of pancreatic markers while inhibition of activin/
TGF-β signalling by SB had the opposite effect (Fig. 2a–g),
demonstrating for the first time that activin/TGF-β signal-
ling inhibits pancreatic specification in vitro. Interestingly,
the presence of SB was only required for the first 3 days of
differentiation, indicating that activin/TGF-β signalling
acted on the earliest steps of pancreatic specification pre-
ceding PDX1 expression. Together, these results show that
RA acts as an inductive signal driving the differentiation of
DE cells towards the pancreatic lineage, while TGF-β sig-
nalling pathways (i.e. activin and BMP) act as a potent
inhibitor of this cell fate choice.
Inhibition of activin/TGF-β induces differentiation of endo-
derm into a near homogenous population of pancreatic
endoderm following a native path of development Based
on the results described above, we established a four-step
protocol to differentiate hESCs into pancreatic endoderm
using defined culture media (Def-Panc, Fig. 1). During the
first step (days 1–3), hESCs were grown in CDM supple-
mented with activin/BMP/FGF2/LY294002 (a phosphoino-
sitide 3-kinase inhibitor) [20]. The resulting cells were
positive for the expression of DE markers including
SOX17, CXCR4, HEX (also known as HHEX), FOXA2 and
EOMES, and simultaneously negative for the expression of
the pluripotency markers POU5f1 (also known as OCT3/4),
NANOG and SOX2 and the primitive streak markers T
(brachyury) and MIXL1 (Fig. 2h–m and ESM Fig. 1p–af).
The second step of the Def-Panc protocol involved growing
DE cells in the presence of RA/noggin/FGF10/SB431542
for 3 days (days 4–6). The resulting cells expressed HNF1B
FOXA2, HNF4A, RFX6 and HLXB9 (Fig. 2i–m and ESM
Fig. 1p–z), all of which mark the foregut during early
mammalian development.
Notably, the expression of HLXB9 and the absence of
HEX expression suggested a dorsal identity for these foregut
cells, while the absence of CDX2 excluded the presence of
midgut or hindgut cells (Fig. 2k, ESM Fig. 1x and data not
shown). In the third step of the protocol, DF cells were
grown for three additional days in the presence of RA/
noggin/FGF10/cyclopamine (days 7–9). The resulting cells
expressed a combination of foregut markers (HNF1B,
SOX2, FOXA2 and HLXB9) and pancreatic endoderm
markers (SOX9, HNF6, PTF1A and PDX1) (Fig. 2i–l and
ESM Fig. 1s–af). The expression of pancreatic endoderm
markers was further reinforced in the fourth step of the
protocol by the addition of FGF10 for 3 days (days 10–
12). The resulting cells expressed NKX6.1, SOX9, HNF6,
PTF1A, PDX1, HNF1B, SOX2 and FOXA2, while the ex-
pression of HLXB9 was strongly diminished (Fig. 2i–m and
ESM Fig. 1a,b). FACS analyses performed at the end of
step 1 showed that the DE-enriched cells were homoge-
neously positive for CXCR4 and after the fourth step of
the protocol (day 12), 80% of cells expressed PDX1
(Fig. 2n,o). Immunostaining analyses also confirmed that
PDX1 was coexpressed with SOX9, HNF6, HNF4, NKX6.1
and GATA4 (Fig. 2p–t) in approximately 80% of the cells
generated. Together, these results indicate that the Def-Panc
protocol drives differentiation of hESCs towards a near
homogenous population of pancreatic endoderm cells fol-
lowing successive events of specifications reminiscent of
those that occur during pancreatic development.
PDX1 endoderm generated in defined culture conditions
can differentiate into insulin secreting cells in vitro and in
vivo To confirm the capacity of pancreatic endoderm cells
to differentiate further towards the endocrine lineage,
PDX1-expressing cells obtained at the end of stage 4 were
grown for six additional days in culture conditions previ-
ously shown to stimulate endocrine cell differentiation [3].
qPCR analyses showed that PDX1 expression decreased
after 3 days, while expression of NGN3 and hormonal
markers (insulin, glucagon and somatostatin) progressively
increased (Fig. 2i–m and ESM Fig. 1ac–af). By day 18, 11%
of cells stained positive for C-peptide (Fig. 3a). Interesting-
ly, these hESC-derived insulin-expressing cells were able to
release C-peptide upon glucose stimulation, mimicking in-
sulin release by pancreatic beta cells (Fig. 3c). Nonetheless,
the expression of hormonal markers (insulin, somatostatin
and glucagon, ESM Fig. 2a–k) was relatively low when
compared with that of human adult islets cells, while the
expression of markers specific to endocrine progenitors was
maintained (NKX6.1, NGN3 and SOX9, ESM Fig. 2a–k).
Furthermore, a fraction of C-peptide-expressing cells was
also positive for glucagon or somatostatin (Fig. 3b).
Polyhormonal expression could mark islet cells of em-
bryonic origin [25], thereby confirming that our in vitro
culture conditions are not sufficient to generate fully func-
tional endocrine cells. To overcome this limitation of the in
vitro system, pancreatic endoderm cells obtained after
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12 days of differentiation were injected under the kidney
capsule of NOD/SCID mice to provide an environment
known to favour their differentiation into endocrine cells
[3]. A low level of human C-peptide was detected in the
blood stream of three out of eight transplanted animals as
soon as 12 weeks after transplantation (negative control0
0.021 ng/ml; mouse 100.1 ng/ml, mouse 200.43 ng/ml,
mouse 300.1635 ng/ml) (Fig. 3d). In addition, histology
analyses performed after 19 weeks of differentiation in
vivo revealed the presence of islet-like clusters with cells
containing glucagon and C-peptide (Fig. 3e–i). Together,
these results demonstrate that pancreatic endoderm cells
generated with the Def-Panc protocol have the capacity
to differentiate further into endocrine cells and thus rep-
resent early pancreatic progenitors. Finally, similar results
were obtained with three hIPSCs lines (ESM Fig. 3),
indicating that the Def-Panc protocol could be success-
fully used to produce pancreatic progenitors from diverse
hPSCs.
Activin/TGF-β drives differentiation of endoderm cells into
hepatic progenitors, which can differentiate into fetal
hepatocytes During screening of the culture conditions de-
scribed above, we noted that DE cells grown in the presence
of activin acquired the appearance of fetal hepatocytes with
large darkened cytoplasmic space and canaliculi-like struc-
tures (data not shown). Further analyses confirmed that DE
cells grown in the presence of activin for 5 days expressed
genes marking the ventral foregut (VF), the site of liver bud
formation (HEX, SOX17, HNF4A, FOXA1, FOXA2 and
TBX3 in Fig. 4a–h). Conversely, inhibition of activin by
SB decreased the expression of HNF4A, SOX17, HEX and
TBX3, while blocking known hepatic inducers such as FGF
signalling also decreased the expression of liver bud genes
such as HEX, SOX17 and TBX3 (Fig. 4i–l). Surprisingly,
noggin only induced a moderate decrease in HNF4A expres-
sion, suggesting that BMP signalling might have a limited
function in hepatic specification in vitro. Alternatively, un-
known signalling pathways could activate the same
programme of differentiation. Considered together, these
results suggest that the combined effect of activin, BMP
and FGF is necessary to fully promote hepatic specification
of DE cells in vitro.
Based on this observation, we developed a three-step
protocol to generate hepatocytes from hPSCs in defined
culture conditions (Def-Hep, Fig. 1). The first step of the
Def-Hep protocol consisted of differentiating hESCs into
DE cells, as described above, while the second step involved
promoting DE specification towards the hepatic lineage
using first activin alone for 3 days and then activin com-
bined with BMP4 and FGF10. In the third step of the Def-
Hep protocol, hepatic endoderm cells were grown for 15
additional days in the presence of oncostatin M and hepa-
tocyte growth factor, two growth factors known to control
hepatoblast differentiation into hepatocytes. Accordingly,
the cells generated with the Def-Hep protocol expressed
hepatocyte markers such as ALB, AAT, αAPOF, TAT,
Fig. 3 Pancreatic progenitors generated from the DF can differentiate
into hormone-expressing cells in vitro and in vivo. (a, b) Expression of
hormonal markers C-peptide (C-Pep), glucagon (GCG) and somato-
statin (SST) in pancreatic endoderm grown for 6 days (day 18) in
culture conditions permissive for endocrine specification. Scale bar
50 μm. (c) C-peptide secretion upon high-glucose (diamond)
(22 mmol/l) stimulation in culture medium of endocrine cells generated
from pancreatic endoderm (day 18). Data are presented as average of
three biological replicates and error bars indicate standard deviation.
Cells grown in low glucose (square) (2.2 mmol/l) were used as nega-
tive control. (d) Mice transplanted with pancreatic progenitors (day 12)
were injected intraperitoneally with glucose 20 weeks after transplan-
tation. Blood samples were taken at indicated time for C-peptide
measurement using ELISA. (e–i) Immunostaining showing the expres-
sion of pancreatic markers in the kidney capsule of a mouse engrafted
with pancreatic endoderm cells (day 12) and then differentiated for
20 weeks in vivo. (e) A kidney capsule 20 weeks after transplantation,
showing the absence of teratomas or overgrowth. (f) A graft containing
an islet-like structure with cells expressing C-peptide. (g) Higher
magnification of the C-peptide expressing cells shown in (f). (h)
Graft-containing cells expressing glucagon. (i) Immunostaining analy-
ses for glucagon (green fluorescence, GCG) and insulin (red flores-
cence, INS) of pancreatic progenitors on day 12, differentiated in vivo
for 19 weeks. DAPI staining (blue fluorescence) marks nuclei
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TDO2, TTR, HNF4A and HEX (Fig. 5a–j). These observa-
tions were confirmed by immunostaining and FACS analy-
ses, which showed homogenous coexpression of ALB,
CK18, AAT and AFP (Fig. 5k–m). These cells also displayed
functional characteristic of hepatocytes, such as: (i) albumin
and α-1-antitrypsin secretion (Fig. 5n–o); (ii) CYP3A4 ac-
tivity inducible by dexamethasone (Fig. 5p); (iii) cholesterol
uptake; and (iv) glycogen storage (Fig. 5q–r). Together,
these data demonstrate that activin drives DE specification
towards VF-like cells and then hepatic endoderm, which has
the capacity to differentiate into cells displaying character-
istics of fetal hepatocytes.
HEX and HLXB9 knockdown during pancreatic and hepatic
differentiation of hESCs blocks hepatic and pancreatic dif-
ferentiation, respectively We then decided to take advantage
of the Def-Panc and Def-Hep culture systems to study the
mechanisms by which activin can control the cell-fate
choice between the pancreatic and hepatic lineages. For that,
we performed gene-expression profiling experiments to
identify genes that were up- or downregulated by the pres-
ence of activin during pancreatic specification. These anal-
yses revealed that activin could activate or block the
expression of a broad number of genes, including HEX
and HLXB9 (Fig. 6a), that are known to be essential for
foregut development. Thus, we hypothesised that activin
could direct DE specification by controlling the expression
of these transcription factors. To test this hypothesis, we
knocked down HEX or HLXB9 levels in hESCs using
stable expression of small hairpin (sh)RNA. The resulting
hESC sublines (shHEX-hESCs and shHLXB9-hESCs) were
then differentiated as described in Fig. 1. qPCR analyses
Fig. 4 Activin induces
specification of DE into VF.
(a–f) Expression of VF and
liver bud markers in DE cells
grown for 5 days in the
presence of activin. All
time points normalised to
undifferentiated hESC (day 0).
(g, h) Immunostaining analyses
showing the coproduction of
HEX, SOX17 and CXCR4 in
hESCs differentiated into VF
using activin (day 6). Scale bar
50 μm. (i–l) qPCR analyses
showing that inhibition of
activin signalling by SB, BMP
by noggin (Nog) and FGF by
SU5402 (SU) decreases the
expression of hepatic markers
in DE cells. All data points
normalised to VF cells cultured
in activin (50 ng/ml; A50)
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showed that knockdown of HEX levels during VF differen-
tiation (Fig. 6b) was systematically associated with down-
regulation of hepatic markers such as AFP and albumin
(Fig. 6c–k). A similar decrease was not observed with DE
cells derived from shHLXB9-hESCs or DE cells derived
from hESCs stably overexpressing a non-targeting shRNA
(shScramble-hESCs) (Fig. 6c, f and i, and data not shown).
However, we also observed that reduced HEX expression
Fig. 5 Differentiation of
hESC-derived DE into fetal
hepatocytes in defined culture
conditions. (a–j) Expression
of hepatocyte markers in DE
cells grown for 25 days in
conditions inductive for hepatic
differentiation. Data were
normalised to undifferentiated
hESCs (day 0). (k) FACS
analyses showing the
coproduction of albumin
(ALB), α1-antitrypsin (AAT)
and α1-fetoprotein (AFP) in
hESC-derived fetal hepatocytes
(day 25). (l, m) Immunostaining
analyses showing the levels of
ALB, cytokeratin 18 (CK18) and
AAT in hESC-derived fetal
hepatocytes (day 25). Scale bar
50 μm. (n, o) ELISA analyses
showing AAT (n) and albumin
(o) secretion in culture media of
hESC-derived fetal hepatocytes.
Fresh culture medium was used
as negative control. (p) Inducible
activity of CYP3A4 by
dexamethasone (DEX) in
hESC-derived fetal hepatocytes.
(q, r) Diagnostic Immunology
Laboratories assay showing
uptake of cholesterol (q) and
periodic acid Schiff staining
showing glycogen storage (r) in
hESC-derived fetal hepatocytes.
Scale bar 50 μm
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increased cell death during VF differentiation (Fig. 6l).
Therefore, HEX expression appears to be necessary for the
survival and differentiation of VF-like cells towards the
hepatic lineage in vitro. Finally, shHEX-hESCs were able
to differentiate into pancreatic endoderm expressing succes-
sively HLXB9 and PDX1 (Fig. 6m,n).
Similar experiments performed with shHLXB9-hESCs
showed that knockdown of HLXB9 levels during foregut
differentiation strongly decreased the expression of pancre-
atic endoderm markers, including PDX1/SOX9 (Fig. 7a–g).
Interestingly, a decrease in HLXB9 expression did not affect
the expression of foregut makers such as HNF4A, FOXA2
and HNF1B (Fig. 7a–f), suggesting that HLXB9 is not
required for DF specification while being necessary for its
differentiation towards the pancreatic lineage. Importantly,
HLXB9 is not expressed during hepatic differentiation
(Fig. 7h), and thus DE cells generated from shHLXB9-
hESCs were able to differentiate into VF-like cells and into
hepatic endoderm when grown in the presence of activin
(data not shown).
Collectively, these results recapitulate studies performed
in the mouse embryo showing that absence of HEX disrupts
hepatic bud development without affecting dorsal pancreatic
specification, while HLXB9 is necessary for induction of
PDX1 expression in the pancreas [26]. Therefore, they
demonstrate the general application of our culture system
in modelling DE development and studying early organo-
genesis of the pancreas and liver in vitro.
Discussion
Robust protocols allowing for the production of homoge-
nous populations of liver and pancreatic progenitors from
hPSCs under culture conditions compatible with clinical
applications have not yet been established. Available
Fig. 6 HEX is necessary for
the hepatic specification of VF
in vitro. (a) Gene expression
profile of DE cells grown for
36 h in the presence activin/RA/
noggin/FGF (D4.5A) or SB/
RA/noggin/FGF (D4.5SB).
(b) qPCR analyses showing
knockdown of HEX in
shHEX-hESCs (grey bar,
shHEX98; white bar, shHEX02
[not visible as there was no
expression compared with
control]) differentiating
into hepatic endoderm.
ShScramble-hESCs were used
as negative control (black bar).
All time points normalised to
undifferentiated shScramble.
(c–k) qPCR analyses showing
the effect of HEX knockdown
on the hepatic specification of
VF cells. All time points
normalised to undifferentiated
shScramble (shSCRAM).
shScramble (c, f, i), shHEX98
(d, g, j) and shHEX02 (e, h, k).
(l) Fraction of apoptotic cells in
shScramble-hESCs (black bar)
and in shHEX-hESCs (dark
grey bar, HEX98; light grey
bar, HEX02) differentiating into
hepatic endoderm. (m, n)
Expression of pancreatic
markers in shHEX-hESCs
differentiating into pancreatic
endoderm (black bar,
shScramble; dark grey bar,
HEX98; light grey bar,
HEX02 open box)
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methods often contain undefined animal products such as
feeders or FBS. To address these challenges, we screened
defined culture conditions to differentiate human DE into a
near homogenous population of pancreatic and liver endo-
derm from multiple hPSC lines. The result of this screening
shows that RA has an essential function in promoting
pancreatic specification while BMP signalling blocks the
expression of the pancreatic marker PDX1, reinforcing
previous studies [21, 22]. However, our results concerning
the function of FGF signalling contradict those of previous
studies [27] by suggesting that FGF acts as a permissive
rather than an inductive signal of pancreatic specification.
This apparent divergence might be explained by the
absence in our culture conditions of feeders, serum and
Matrigel, all of which contain unknown components that
are likely to interfere with FGF signalling. In addition, we
observed that inhibition of FGF signalling decreases cell
survival of pancreatic progenitors, thus justifying the use
of FGFs in our protocol. More importantly, our analyses
also revealed that activin/TGF-β controls DE cell fate
choice towards the pancreas lineage by inhibiting DF
specification while promoting the hepatic lineage. Previous
studies have shown that TGF-β signalling controls ventral
pancreatic bud induction in the mouse embryo [15] and,
thus, our data demonstrate for the first time that similar
mechanisms could occur in the dorsal pancreas, confirming
the interest of our culture system in modelling foregut
development in vitro. Interestingly, a recent report has
shown that inhibition of TGF-β signalling can block gut
specification induced by WNT signalling [24] and also
promote endocrine differentiation of PDX1-expressing pro-
genitors [28, 29]. Thus, TGF-β can control different stages
of pancreatic development. Further studies will be necessary
to fully understand the successive functions of TGF-β path-
ways during primitive tube patterning and organogenesis.
Our results also show that activin/TGF-β signalling
directs hepatic vs pancreatic specification by controlling
transcription factors directing foregut differentiation, such
as HEX and HLXB9. Interestingly, we recently identified
HEX as a direct target of Smad2/3 using chromatin
immunoprecipitation-sequencing analyses in differentiating
DE cells [30], and thus activin/TGF-β signalling could
Fig. 7 HLXB9 is necessary for
pancreatic specification of DF
in vitro. (a–f) qPCR analyses
showing the effect of hHLXB9
knockdown on pancreatic
differentiation. All points
normalised to undifferentiated
shScramble. (g) Expression of
pancreatic endoderm markers
in shHLXB9-hESCs grown
for 12 days in culture
conditions inductive for
pancreatic differentiation.
Scale bar 50 μm. (h)
Expression of HLXB9 during
hepatic differentiation. hESCs
were grown for 25 days in
culture inductive for hepatic
differentiation and analysed for
the expression of HLXB9 every
6 days using qPCR. hESCs
were used as negative control
and pancreatic progenitors
differentiated for 9 days
(Panc D9) were used as a
positive control
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‘directly’ control hepatic specification by maintaining HEX
expression during DE development. Our findings are in
keeping with a recent demonstration that HEX plays a
pivotal role in the induction of liver development from
mouse embryonic stem-cell-derived endoderm [31], and
the observation that transient overexpression of HEX in
hESCs and hIPSCs enhances the formation of hepatoblasts
[32]. However, our findings also suggest an essential func-
tion for HEX in the early stage of hepatic specification,
which differs from the results obtained with mouse embryos
showing that HEX is not necessary for liver bud induction
[33]. Nevertheless, these experiments were performed either
with whole embryos or with culture explant, mixing several
tissues grown in culture media containing serum and un-
known factors. Our culture system is based on defined
culture conditions that might not contain all of the necessary
factors to maintain hepatic endoderm in the absence of
HEX. This hypothesis is in agreement with recent studies
indicating that BMP and HEX display a synergistic effect on
hepatic specification [31].
Similarly, activin/TGF-β signalling could inhibit pancre-
atic specification by blocking HLXB9 expression, which is
necessary for the subsequent induction of PDX1 [10, 11].
This mechanism is likely to involve other factors since
Smad2/3 was not detected on the HLXB9 promoter upon
DE differentiation and thus cannot play a ‘direct’ repressive
function. The importance of HLXB9 also indicates that cells
generated in vitro have a DF origin, since HLXB9 is not
necessary for ventral bud development [10, 11]. Neverthe-
less, further studies will be necessary to confirm this
hypothesis and to identify additional culture conditions for
generating ventral pancreatic cells.
Finally, these results have important practical signifi-
cance since protocols currently available to generate pan-
creatic cells from hPSCs often rely on feeders, Matrigel and
serum, all of which represent a potential source of TGF-β
signalling with the capacity to compromise pancreatic spec-
ification. Moreover, recent studies have shown that endog-
enous levels of nodal expression might determine the
capacity of specific hIPSC lines to differentiate into meso-
dermal derivatives [34]. Such differences in the endogenous
level of nodal/TGF-β growth factors could affect the capac-
ity of diverse hPSC lines to differentiate into pancreatic
endoderm, and the inhibition of this signalling pathway with
SB could bypass this limitation. Accordingly, we recently
differentiated ten hIPSC lines into pancreatic endoderm
using our four-step protocol, and observed that only those
hIPSC lines that failed to differentiate into DE (two out of
ten) also lacked the ability to differentiate into pancreatic
cells (M. Brimpari, University of Cambridge, Cambridge,
UK and L. Vallier, personal observations).
Another advantage of inhibiting TGF-β signalling during
pancreatic specification resides in the possibility of
eliminating contaminating pluripotent cells. Indeed, we
and others have extensively demonstrated that inhibition of
activin/nodal/TGF-β signalling induces differentiation of
hPSCs [35]. Thus, inhibition of activin during DE specifi-
cation could decrease contamination by undifferentiated
cells. Accordingly, we have failed to observe teratoma
formation in mice transplanted with pancreatic progeni-
tors. Therefore, inhibiting activin signalling during pan-
creatic specification could allow for the generation of
‘safer’ pancreatic progenitor for potential cell-based
therapy.
To conclude, our study could greatly facilitate the pro-
duction of homogenous populations of pancreatic and liver
cells in defined culture conditions for clinical applications.
However, this culture system also provides a robust and
efficient in vitro model of development to study human
endoderm differentiation.
Funding This work was funded by Medical Research Council senior
non-clinical fellowships (CH-HC, LV), the Cambridge Hospitals
National Institute for Health Research Biomedical Research Center
(LV), EU grant LivES (NR-FH), JDRF (KD, LV and CH-HC) and
MOE Taiwan (CH-HC). Since contributing to this work, MWBT has
become an employee of Celgene Research SLU (part of the Celgene
Corporation)
Duality of interest The authors declare that there is no duality of
interest associated with this manuscript.
Contribution statement CH-HC and NR-FH contributed equally to
this study. All authors participated in concept and design of the study
as well as collection, assembly and interpretation of data. CH-HC,
NR-FH, KD and LV prepared the manuscript and all authors revised,
edited and approved the final version of the manuscript.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and the source are credited.
References
1. Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic
stem cell lines derived from human blastocysts. Science 282:1145–
1147
2. Takahashi K, Tanabe K, Ohnuki M et al (2007) Induction of
pluripotent stem cells from adult human fibroblasts by defined
factors. Cell 131:861–872
3. D’Amour KA, Bang AG, Eliazer S et al (2006) Production of
pancreatic hormone-expressing endocrine cells from human
embryonic stem cells. Nat Biotechnol 24:1392–1401
4. Jiang W, Shi Y, Zhao D et al (2007) In vitro derivation of
functional insulin-producing cells from human embryonic stem
cells. Cell Res 17:333–344
5. Maehr R, Chen S, Snitow M et al (2009) Generation of pluripotent
stem cells from patients with type 1 diabetes. Proc Natl Acad Sci
USA 106:15768–15773
Diabetologia
6. Zhang D, Jiang W, Liu M et al (2009) Highly efficient differenti-
ation of human ES cells and iPS cells into mature pancreatic
insulin-producing cells. Cell Res 19:429–438
7. Kroon E, Martinson LA, Kadoya K et al (2008) Pancreatic
endoderm derived from human embryonic stem cells generates
glucose-responsive insulin-secreting cells in vivo. Nat Biotechnol
26:443–452
8. Kelly OG, Chan MY, Martinson LA et al (2011) Cell-surface
markers for the isolation of pancreatic cell types derived from
human embryonic stem cells. Nat Biotechnol 29:750–756
9. Zaret KS, Grompe M (2008) Generation and regeneration of cells
of the liver and pancreas. Science 322:1490–1494
10. Harrison KA, Thaler J, Pfaff SL, Gu H, Kehrl JH (1999) Pancreas
dorsal lobe agenesis and abnormal islets of Langerhans in Hlxb9-
deficient mice. Nat Genet 23:71–75
11. Li H, Arber S, Jessell TM, Edlund H (1999) Selective agenesis of
the dorsal pancreas in mice lacking homeobox gene Hlxb9. Nat
Genet 23:67–70
12. Jonsson J, Carlsson L, Edlund T, Edlund H (1994) Insulin-
promoter-factor 1 is required for pancreas development in mice.
Nature 371:606–609
13. Offield MF, Jetton TL, Labosky PA et al (1996) PDX-1 is required
for pancreatic outgrowth and differentiation of the rostral
duodenum. Development 122:983–995
14. Sherwood RI, Chen TY, Melton DA (2009) Transcriptional
dynamics of endodermal organ formation. Dev Dyn 238:29–42
15. Wandzioch E, Zaret KS (2009) Dynamic signaling network for the
specification of embryonic pancreas and liver progenitors. Science
324:1707–1710
16. Rashid ST, Corbineau S, Hannan N et al (2010) Modeling
inherited metabolic disorders of the liver using human induced
pluripotent stem cells. J Clin Invest 120:3127–3136
17. Brons IG, Smithers LE, Trotter MW et al (2007) Derivation of
pluripotent epiblast stem cells from mammalian embryos. Nature
448:191–195
18. Touboul T, Hannan NR, Corbineau S et al (2010) Generation of
functional hepatocytes from human embryonic stem cells under
chemically defined conditions that recapitulate liver development.
Hepatology 51:1754–1765
19. Vallier L, Rugg-Gunn PJ, Bouhon IA, Andersson FK, Sadler AJ,
Pedersen RA (2004) Enhancing and diminishing gene function in
human embryonic stem cells. Stem Cells 22:2–11
20. Teo AK, Arnold SJ, Trotter MW et al (2011) Pluripotency factors
regulate definitive endoderm specification through eomesodermin.
Genes Dev 25:238–250
21. Mfopou JK, Chen B, Mateizel I, Sermon K, Bouwens L (2010)
Noggin, retinoids, and fibroblast growth factor regulate hepatic or
pancreatic fate of human embryonic stem cells. Gastroenterology
138:2233–2245. e14
22. Cai J, Yu C, Liu Y et al (2010) Generation of homogeneous PDX1
(+) pancreatic progenitors from human ES cell-derived endoderm
cells. J Mol Cell Biol 2:50–60
23. Wells JM, Melton DA (2000) Early mouse endoderm is patterned
by soluble factors from adjacent germ layers. Development
127:1563–1572
24. Spence JR, Mayhew CN, Rankin SA et al (2011) Directed differ-
entiation of human pluripotent stem cells into intestinal tissue in
vitro. Nature 470:105–109
25. Polak M, Bouchareb-Banaei L, Scharfmann R, Czernichow P
(2000) Early pattern of differentiation in the human pancreas.
Diabetes 49:225–232
26. Habener JF, Kemp DM, Thomas MK (2005) Minireview: tran-
scriptional regulation in pancreatic development. Endocrinology
146:1025–1034
27. Ameri J, Stahlberg A, Pedersen J et al (2010) FGF2 specifies
hESC-derived definitive endoderm into foregut/midgut cell
lineages in a concentration-dependent manner. Stem Cells
28:45–56
28. Nostro MC, Sarangi F, Ogawa S et al (2011) Stage-specific
signaling through TGF{beta} family members and WNT regulates
patterning and pancreatic specification of human pluripotent stem
cells. Development 138:861–871
29. Kunisada Y, Tsubooka-Yamazoe N, Shoji M, Hosoya M (2012)
Small molecules induce efficient differentiation into insulin-
producing cells from human induced pluripotent stem cells. Stem
Cell Res 8:274–284
30. Brown S, Teo A, Pauklin S et al (2011) Activin/nodal signaling
controls divergent transcriptional networks in human embry-
onic stem cells and in endoderm progenitors. Stem Cells
29:1176–1185
31. Kubo A, Kim YH, Irion S et al (2009) The homeobox gene Hex
regulates hepatocyte differentiation from embryonic stem cell-
derived endoderm. Hepatology 51:633–641
32. Inamura M, Kawabata K, Takayama K et al (2011) Efficient
generation of hepatoblasts from human ES cells and iPS cells by
transient overexpression of homeobox gene HEX. Mol Ther
19:400–407
33. Bort R, Martinez-Barbera JP, Beddington RS, Zaret KS (2004)
Hex homeobox gene-dependent tissue positioning is required
for organogenesis of the ventral pancreas. Development
131:797–806
34. Ramos-Mejia V, Melen GJ, Sanchez L et al (2010) Nodal/activin
signaling predicts human pluripotent stem cell lines prone to
differentiate towards the hematopoietic lineage. Mol Ther
18:2173–2181
35. Vallier L, Mendjan S, Brown S et al (2009) Activin/nodal signal-
ling maintains pluripotency by controlling Nanog expression.
Development 136:1339–1349
Diabetologia
Inhibition of Activin/Nodal signalling is necessary for pancreatic differentiation of 
human pluripotent stem cells. 
 
ELECTRONIC SUPPLEMENTARY MATERIALS. 
 
Candy Cho*, Nicholas Hannan*, and colleagues.  
 
SUPPLEMENTARY METHODS 
hESCs and hIPSCs culture conditions. 
hESCs and hIPSCs maintained in chemically defined medium (CDM) supplemented with 
Activin A (10ng/ml) and FGF2 (12ng/ml) .  Cells were generally grown on tissue culture 
plates coated with gelatine and 10% FBS containing medium. However, human fibronectin 
was used occasionally as described previously. CDM contains 250 ml DMEM-F12 (GIBCO 
31765-027) and 250mL IMDM (GIBCO 21980-032) mixed 1:1, 5mL concentrated lipids 
(GIBCO 11905), 20uL Mercapto-thio-Glycerol (Sigma M6145), 350uL Insulin (ROCHE 
11376497001), 250uL Transferrin (ROCHE 10652202001), 5mL Pen/Strep (GIBCO 15140-
122), and 2.5gr of bovine serum albumin, cohn Fraction V (Europa Bioproducts). BSA can be 
replaced by 0.5gr Polyvinylalcohol (SIGMA P8136) to obtain a fully defined medium. Prior 
to splitting, cells were washed once with PBS, collagenase was added and cells incubated at 
37C for 20 minutes. When colonies detached from the tissue culture plate they were 
transferred to a 15ml tube, washed twice with 10ml of CDM and then resuspended in a 
volume to obtain a 1:6-10 split ratio. Differentiation was carried out as described in Figure 1. 
DE was induced by growing hESCs in CDM-PVA + Activin-A (100ng/mL), BMP4 
(10ng/mL), bFGF (20ng/mL) and LY (10 mM) (AFBLy). The CDM-PVA AFBLy cocktail 
was replenished daily, and daily media changes were made during the entire differentiation 
protocol.  
 
hESCs and hIPSCs maintenance and differentiation culture conditions. 
 hESCs (H9 from WiCell) and hIPSCs (BBHX8, A1ATD-1, JRO1D) [16]  were passaged 
weekly using collagenase IV and maintained in chemically defined medium (CDM) 
supplemented with Activin A (10ng/ml) and FGF2 (12ng/ml) as described previously [17]. 
Differentiation was carried out as described in Figure 1. DE was induced by growing hESCs 
in CDM-PVA + Activin-A (100ng/mL), BMP4 (10ng/mL), bFGF (20ng/mL) and LY (10 
M) (AFBLy). The CDM-PVA AFBLy cocktail was replenished daily, and daily media 
changes were made during the entire differentiation protocol. After the DE stage (stage 1), 
cells were cultured in Advanced DMEM (Invitrogen) supplemented with SB-431542 (10 M; 
Tocris), FGF10 (50 ng/ml; AutogenBioclear), all-trans retinoic acid (RA, 2 M; Sigma) and 
Noggin (50 ng/ml; R&D Systems) for 3 days. For stage stage 3, the cells were cultured in 
Advanced DMEM supplemented with human FGF10 (50 ng/ml; AutogenBioclear), all-trans 
retinoic acid (RA, 2 uM; Sigma), KAAD-cyclopamine (0.25 uM; Toronto Research 
Chemicals) and Noggin (50 ng/ml; R&D Systems) for 3 days. For Stage 4, the cells were 
cultured in human FGF10 (50 ng/ml; R&D Systems) for 3 days. For maturation of pancreatic 
progenitors, cells were grown in Advanced DMEM + 1% vol/vol B27 and DAPT (1 mM) for 
3 days and for 3 additional days in Advanced DMEM + 1% vol/vol B27. 
 
HEX and HLXB9 Knockdown. 
hESCs (H9) were stably transfected with expression vectors for ShRNA directed against 
HEX and HLXB9 (Open Biosystem) using Lipofectamine 2000 (Invitrogen) [19]. Stably 
transfected cells were then selected using puromycin and the resulting colonies were 
individually picked for further analyses. 100 hESC sublines  (10 hESC sublines for each 
ShRNA expression vector) were analysed for the knock down of HEX and HLXB9 after 
differentiation into hepatic or pancreatic endoderm respectively. Further analyses were 
systematically performed on at least 2 hESCs sublines expressing different ShRNA 
sequences. 
 
 
Microarray profiling 
Total RNA was extracted using RNeasy® Mini Kit according to manufacturer’s protocol 
(Qiagen). RNA samples were first assessed for their RNA integrity prior to hybridisation on 
the microarray. Five biological replicate samples for each condition among Day 4.5 and Day 
4.5 -Activin+SB differentiated hESCs were hybridised to Illumina Human HT-12 v4.0R1 
Expression BeadChips using manufacturer’s standard protocols. BeadChip probe-sets that did 
not pass the Illumina signal detection statistic at a threshold of p < 0.01 in all sample 
replicates of at least one sample group were removed from further analysis. For all samples, 
the remaining probe-sets were background corrected, normalized and summarized using 
default parameters of the RMA model 
23
. Array processing was performed using the 
beadarray package of the Bioconductor (http://www.bioconductor.org) suite of software for 
the R statistical programming language (http://www.r-project.org). Probe-sets were annotated 
using transcript information made available by the manufacturer 
(http://www.switchtoi.com/annotationfiles.ilmn). The raw microarray data described has been 
uploaded to the ArrayExpress repository (EBI; http://www.ebi.ac.uk/microarray-as/ae/). 
Experiment name: Vallier hESC Endoderm. ArrayExpress accession: E-MEXP-2373 
Analysis of Differential Regulation: The moderated t-statistic of 
24
, implemented in the limma 
package of Bioconductor, was employed to assess the significance of differential gene 
(probe-set) expression between sample groups. In order to reduce errors associated with 
multiple hypothesis testing on such a scale, the significance p-values obtained were converted 
to corrected q-values using the FDR method of 
25
. Probe-sets with associated q < 0.001 (FDR 
0.1%) were deemed to exhibit significant differential expression between sample groups.  
Data Visualisation: Heat maps of gene expression were created by importing relevant subsets 
of RMA processed microarray gene expression data into the Java Treeview data visualisation 
package (http://sourceforge.net/projects/jtreeview/).  In the case wherein a gene is 
represented by more than one probe-set on the array, a single probe-set was chosen to 
represent gene expression in the heat map according to highest mean expression over all 
samples (i.e. the most reliable sample hybridization regardless of group membership). 
The raw microarray data described has been uploaded to the ArrayExpress repository (EBI; 
http://www.ebi.ac.uk/microarray-as/ae/). 
 
Enzyme linked immunosorbent assay (ELISA). 
hESCs grown for 18 days in culture conditions inductive for pancreatic specification 
were cultured in differentiation medium without insulin for 24 h prior to Glucose stimulation. 
Cells were then washed three times in PBS and pre-incubated in DMEM supplemented with 
2.2 mM glucose (Invitrogen) for 60 min at 37ºC. To estimate glucose‐induced insulin 
secretion, pre-incubated cells wre grown in DMEM containing 22 mM glucose or 
alternatively 2.2 mM glucose for 15 or 60 minutes. Supernatants were collected for 
determination of C-peptide release. ELISA analyses were performed using the Mercodia 
Ultrasensitive C-peptide ELISA kit (Mercodia).  
Concerning Abumin and ATT secretion assays, High binding surface COSTAR 96-
well plates (Corning, NY, USA) were coated overnight with affinity-purified rabbit 
polyclonal antibodies against α1-antitrypsin (Abcam 31657, Cambridge, UK) and Albumin 
(Abcam 87564, Cambridge, UK) at 2 μg/ml in carbonate/bicarbonate buffer 
(Na2CO3/NAHCO3, pH 9.5). After washing (0.9% w/v NaCl, 0.05% v/v Tween 20), the 
plates were blocked for two hours in blocking buffer (PBS, 0.25% w/v BSA, 0.05% v/v 
Tween 20). Culture medium were diluted in blocking buffer and 50μl added to each well then 
incubated for two hours. After washing, the wells were incubated with corresponding 
monoclonal antibodies (1μg/ml diluted in blocking buffer), and incubated for two hours. 
Bound monoclonal antibodies were detected with rabbit anti-mouse IgG HRP-labelled 
antibody (Sigma Aldrich, Haverhill, UK, 1:20,000) for one hour. The reaction was developed 
with TMB liquid substrate (Sigma Aldrich, Haverhill, UK) for 10 minutes in the dark and the 
reaction was stopped with 1 M H2SO4. Absorbance was read at 450nm on a Thermo-max 
microplate reader (Molecular Devices, Sunnyvale, CA, U.S.A.).  
 
Immunostaining 
hESCs or their differentiated progenitors were fixed for 20 minutes at 4
o
C in 4% 
paraformaldehyde and then washed three times in PBS. Cells were incubated for 20 minutes 
at room temperature in PBST (0.1% Triton X100; Sigma; in PBS) containing 10% donkey 
serum (Serotec Ltd.) and subsequently incubated overnight at 4
o
C with primary antibody 
(Table 11) diluted in 1% donkey serum in PBST. Cells were then washed three times in PBS 
and incubated with secondary antibodies (Table 11) in 1% donkey serum in PBST for 2 hours 
at room temperature. Unbound secondary antibody was removed by three 5 minutes washes 
in PBS. Hoechst 33258 was added to the first wash (Sigma-Aldrich; 1:10,000). For lipid 
visualization a lipid specific stain BODIPY (boron-dipyrromethene; BODIPY® 493/503 
Invitrogen.D-3922) was used. 
 
Flow Cytometry 
Adherent cells at the specific stage of the pancreatic differentiation protocol were washed 
twice in PBS and then incubated for 20 minutes at 37
o
C in cell dissociation buffer 
(Invitrogen, Carlsbad, CA, http://www.invitrogen.com). Cells were dissociated by gentle 
pipetting and resuspended at approximately 0.1-1 x 10
5
 cells per milliliter in PBST + 3% 
normal donkey serum (NDS) containing 0.1% azide (Serotec Ltd.,Oxford, U.K., 
http://www.serotec.com). Cells were then fixed for 20 minutes at 4
o
C in 4% 
paraformaldehyde and then washed three times in PBS. Cells were pelleted and resuspended 
in 2mL of SAP buffer (0.1% (w/v) saponin In Hanks’ Balanced Salt Solution). Cells were 
incubated for 2 hours at room temperature with primary antibody (Table 11) in SAP buffer. 
Cells were then washed three times in PBS +3% NDS and then incubated with secondary 
antibodies (Table 1) in SAP buffer for 2 hours at room temperature. Unbound secondary 
antibody was removed by three washes in PBS. Cells were then analyzed using a FACS 
Calibur machine (BD Biosciences, San Jose, California, USA, 
http://www.bdbiosciences.com). Number of positive cells was recorded as the average from 
three separate experiments. 
 
Table 1: Antibodies and corresponding dilution  
Target protein Dilution Company 
C-PEPTIDE ICC 1:300 ACRIS ANTIBODIES  
CYTOKERATIN 18 ICC 1:100 SANTA CRUZ 
GATA-4 (G-4) ICC 1:100 SANTA CRUZ 
GATA6  ICC 1:100 ABCAM  
GLUCAGON (N-17) ICC 1:100 SANTA CRUZ  
HNF1B (C-20) ICC 1:100 SANTA CRUZ 
HNF3B/FOXA2 ICC 1:100 R&D SYSTEMS 
HNF4 (H-171) ICC 1:100 SANTA CRUZ:  
HNF-6 (H-100) ICC 1:100 SANTA CRUZ 
NGN3 ICC 1:300 R&D SYSTEMS 
NKX6.1 (GS-9A8) ICC 1:50 
THE DEVELOPMENTAL 
STUDIES HYBRIDOMA 
BANK 
PDX-1/IPF1 ICC/ 1:300 R&D SYSTEMS 
PDX-1/IPF1 (IC2419A) FC R&D SYSTEMS 
PRO-INSULIN ICC 1:50 
THE DEVELOPMENTAL 
STUDIES HYBRIDOMA 
BANK  
SOMATOSTATIN ICC 1:200 DAKO  
SOX9 H-90 ICC 1:100 SANTACRUZ:  
ALEXA FLUOR® 488 DONKEY ANTI-
MOUSE IGG (H+L) *2 MG/ML* ICC 1:2000 INVITROGEN 
ALEXA FLUOR® 488 GOAT ANTI-
GUINEA PIG IGG (H+L) *2 MG/ML* ICC 1:2000 INVITROGEN 
ALEXA FLUOR® 488 DONKEY ANTI-
GOAT IGG (H+L) *2 MG/ML* ICC 1:2000 INVITROGEN 
ALEXA FLUOR 568 DONKEY ANTI 
GOAT IGG (H+L) *2 MG/ML* ICC 1:2000 INVITROGEN 
ALEXA FLUOR 568 DONKEY ANTI 
RABBIT IGG (H+L) *2 MG/ML* ICC 1:2000 INVITROGEN 
ALEXA FLUOR® 647 DONKEY ANTI-
GOAT IGG (H+L) *2 MG/ML* FL 1:2000 INVITROGEN 
ALEXA FLUOR® 647 DONKEY ANTI-
RABBIT IGG (H+L) *2 MG/ML* FL 1:2000 INVITROGEN 
APC-conjugated isotype control  FL R&D SYSTEMS 

Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
no
rm
al
ise
d
to
 h
ES
Cs
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
no
rm
al
ise
d
to
 h
ES
Cs
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
no
rm
al
ise
d
to
 h
ES
Cs
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
no
rm
al
ise
d
to
 h
ES
Cs
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
no
rm
al
ise
d
to
 h
ES
Cs
Re
la
tiv
e 
ge
ne
 e
xp
re
ss
io
n 
no
rm
al
ise
d
to
 h
ES
Cs
Pl
ur
ip
ot
en
cy
Pr
im
iti
ve
 S
tr
ea
k
En
do
de
rm
Pa
nc
re
at
ic
 E
nd
od
er
m
En
do
cr
in
e
a
p
b c d e f
g h i j k l
m n o
q r
s t u
v w x
y z aa ab
ac ad ae af
ad
j
g
b c
h
f
k
i
e
050
100
150
BBHX8 BOB8 01D
FoxA2
0
50000
100000
150000
BBHX8 BOB8 01D
GCG
0
10000
20000
30000
40000
BBHX8 BOB8 01D
INS
0
1000
2000
3000
BBHX8 BOB8 01D
PDX1
0
50
100
0 1
C‐
Pe
pt
id
e 
pm
ol
/L
22mM Glucose (hrs)
hIPSC1
0
25
50
0 1
C‐
Pe
pt
id
e 
pm
ol
/L
22mM Glucose (Hrs)
hIPSC2
0
25
50
75
0 1
C‐
Pe
pt
id
e 
(p
m
ol
/L
)
22mM Glucose (hrs)
hIPSC3
Ge
ne
 e
xp
re
ss
io
n 
no
rm
al
ise
d
to
 h
IP
SC
s
D1
8 
(h
IP
SC
2)
D1
8 
(h
IP
SC
3)
D1
8 
(h
IP
SC
1)
D1
8 
(h
IP
SC
1)
D1
2 
(h
IP
SC
1)
hIPSC1   hIPSC2   hIPSC3 hIPSC1   hIPSC2   hIPSC3 hIPSC1   hIPSC2   hIPSC3 hIPSC1   hIPSC2   hIPSC3
70%
3%
PDX1
EV
EN
TS
a b c d
e
f
h
g
i
j
k l m
